Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells $101,118.89 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 3,323 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $101,118.89. Following the transaction, the general counsel now directly owns 144,994 shares of the company’s stock, valued at $4,412,167.42. This trade represents a 2.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Apellis Pharmaceuticals Trading Down 2.5 %

Shares of APLS opened at $30.00 on Friday. Apellis Pharmaceuticals, Inc. has a one year low of $24.34 and a one year high of $71.90. The stock has a 50-day moving average price of $32.08 and a 200 day moving average price of $33.15. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The company has a market capitalization of $3.73 billion, a P/E ratio of -14.78 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The company had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s quarterly revenue was up 78.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.17) EPS. Sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. William Blair initiated coverage on Apellis Pharmaceuticals in a report on Wednesday, October 16th. They set an “outperform” rating for the company. Scotiabank dropped their price target on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group lowered Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective on the stock. in a research note on Tuesday, December 17th. Citigroup dropped their target price on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Evercore ISI raised shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of APLS. Wolverine Asset Management LLC bought a new position in shares of Apellis Pharmaceuticals during the third quarter worth about $27,000. True Wealth Design LLC acquired a new stake in Apellis Pharmaceuticals during the third quarter valued at approximately $27,000. Capital Performance Advisors LLP bought a new position in Apellis Pharmaceuticals during the 3rd quarter worth approximately $56,000. KBC Group NV grew its position in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after acquiring an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after acquiring an additional 781 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).